PubMed Health⌕ Search

Biomedical subjects

C J Falliers

Publications and source records attributed to C J Falliers.

16 recordsLinked to original sources
PubMed1979

Pharmacodynamic and spirometric responses to a sustained-release theophylline capsule.

A prolonged therapeutic effect following a single oral dose of theophylline and maintenance of an adequate therapeutic blood level of theophylline is an important factor in the management of chronic bronchial asthma. Eighteen adult asthmatics, nine of whom were females and nine males, aged between 21-53 years, were given a sustained release theophylline capsule, 250 mg, every 12 hours and pulmonary mechanical functions as well as serum theophylline levels were studied. All patients received Elixophyllin Elixir, 250 mg, and their serum level as well as pulmonary functions were studied and compared to those after receiving the sustained release capsules. In these patients, after isoproterenol inhalation, an average of 25.6% improvement in FEV1 was observed while after placebo there were very minimum changes. At the steady-state of sustained release theophylline capsule administration, an average of 20% improvement of FEV1 was observed at the five hour period and sufficient bronchodilation expressed as FEV1 was observed for a 10-12 hour period. Indeed, a sustained release theophylline capsule fulfilled the requirement that it adequately maintained therapeutic theophylline level of the blood and improved bronchodilation lasting up to 12 hours.

Adult↗
PubMed1978

Controlled assessment of oral bronchodilators for asthmatic children.

Various pulmonary function changes were determined in twenty paediatric patients after a single oral dose of theophylline, ephedrine, or their combination in a double-blind crossover study. The possible contributions of guaifenesin and butabarbital, components of some formulations in clinical use, were also examined. Bronchodilatory efficacy in decreasing order, when compared to placebo, was observed for theophylline-ephedrine and theophylline (nearly comparable), and for ephedrine-butabarbital and ephedrine (nearly comparable). Butabarbital and guaifenesin did not enhance or decrease bronchodilatory effect. Adverse reactions appeared to be more frequently related to ephedrine intake, although no serious reactions were noted.

Administration, Oral↗
PubMed1978

Inhibition of cutaneous and mucosal allergy with phenyltoloxamine.

A dose-and-time related-effect of oral phenyltoloxamine citrate, a Class I, H1 antihistamine compound, has been demonstrated against allergen-induced wheal-and-erythema skin reactions among 10 adults with a diagnosis of allergic rhinitis and seasonal pollinosis. Clinical improvement in the existing symptoms of rhinorrhea, nasal obstruction, pruritus and sneezing, showed a significant correlation with the inhibition of reagin-mediated skin reactivity caused by phenytoloxamine. No adverse side effects were observed. It can be concluded that oral phenyltoloxamine citrate possesses antihistaminic properties and a range of safety which make it a useful agent for the symptomatic management of upper respiratory allergy.

Adolescent↗
PubMed1978

Controlled trial of bronchodilator-mucolytic aerosols, combined and separate.

In seven of 30 ambulatory asthmatics the inhalation of 10% acetylcysteine reduced the FEV1 by more than 10% (range: 14% to 53%). Inclusion of isoproterenol (0.05%) reversed this depression over the entire trial in six of these subjects, while the seventh responded similarly except for the last measurement. It is concluded that the addition of isoproterenol to an acetylcysteine aerosol in the above ratio can eliminate the ventilatory impairment induced by the latter and is therefore indicated for those patients with chronic obstructive lung disease who benefit from a mucolytic agent.

Acetylcysteine↗
PubMed1976

Triamcinolone acetonide aerosols for asthma. I. Effective replacement of systemic corticosteroid therapy.

Triamcinolone acetonide, a water-insoluble corticosteroid preparation in a Freon-propelled metered-dose aerosol, was administered via a specially designed nebulizer to 22 adult patients with severe, chronic asthma. All patients had required oral corticosteroid therapy, daily, for several years, in order to control their incapacitating obstructive airways disease. During 4 wk of treatment with triamcinolone acetonide, taken in 4 daily doses totaling 8 to 28 inhalations (400-1,400 mcg) per day: (1) asthma remained under satisfactory control; (2) oral corticosteroids were stopped in 19 patients and reduced in 2, and 1 patient withdrew from the study; (3) adrenal cortical function returned to normal or near normal levels; (4) spirometric and plethysmographic measurements improved significantly; (5) daily self-measurements of peak expiratory flow showed a marked improvement in median weekly levels, as well as a reduction in daily variability. No immediate undesirable side effects were noted. These observations indicated that more extensive applications of topical corticosteroid therapy are justified as an effective, convenient, and relatively safe method for the preventive management of severe, persistent asthma.

Administration, Intranasal↗
PubMed1976

Pharmacologic modification of induced asthma.

Oral adrenergic substances (e.g., ephedrine) and phosphodiesterase inhibitors (e.g., theophylline) can have a prophylactic effect on natural or experimentally induced asthma by maintaining high levels of cyclic AMP in the target organ cells. This controlled, double-blind study evaluates these drugs alone and in a standard dosage combination in blocking asthma induced by the inhalation of pollen allergens among highly selected patients. The results support the claim that oral adrenergic drugs and xanthines can be useful in the prophylaxis of asthma.

Adult↗